Supervalu announces election of new board members
MINNEAPOLIS — Supervalu has elected Frank (Terry) Savage and Mathew Pendo to its board of directors.
Savage and Pendo were both appointed to the board as designees of Symphony Investors, a Cerberus Capital Management-led investor consortium, under the terms of the tender offer agreement entered into with Symphony Investors and Cerberus in connection with Supervalu’s sale of five banners to an affiliate of Symphony Investors. Symphony Investors owns approximately 20.9% of Supervalu’s outstanding common stock.
Savage is currently a senior advisor to Lazard and the former vice chairman of U.S. Investment Banking at Lazard.
Pendo is currently a managing director at Sandler O’Neill Partners, a boutique investment banking firm focused on the financial services industry.
The board now has 11 members, nine of whom are independent directors under the New York Stock Exchange listing standards.
FDA approves first HPV test for cervical cancer screening
SILVER SPRING, Md. — The Food and Drug Administration on Thursday approved a human papillomavirus DNA test for women 25 years of age and older that can be used alone to help health care professionals assess the need for a woman to undergo additional testing for cervical cancer. The Cobas HPV test is the first and only HPV test approved for primary screening in the United States.
The test uses a sample of cervical cells to specifically identify HPV 16 and HPV 18, while also detecting 12 other types of high-risk HPVs.
“Today’s approval offers women and physicians a new option for cervical cancer screening,” said Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostics and Radiological Health at the FDA’s Center for Devices and Radiological Health. “Roche Diagnostics conducted a well-designed study that provided the FDA with a reasonable assurance of the safety and effectiveness when used as a primary screening tool for cervical cancer.”
Based on results of the Cobas HPV test, women who test positive for HPV 16 or HPV 18 should have a colposcopy, an exam that uses a device to illuminate and magnify the cervix so a physician can observe the cervical cells. Women who test positive for one or more of the 12 other high-risk HPV types should have a Pap test to determine the need for a colposcopy.
The Cobas HPV test is manufactured by Roche Molecular Systems, which is based in Pleasanton, Calif.
Armada Health Care launches new web application solution for specialty pharmacy industry
FLORHAM PARK, N.J. — Armada Health Care, a provider for channel management solutions, commercialization strategies, and support services for the specialty pharmaceutical industry, has announced the launch of a new specialty pharmacy software solution called Vision Armada Analytics.
The tool, which supports multiple pharmacy platforms for API integration, tracks a specialty drug’s path prior to initiation of treatment (pre-dispensed data), during the intake and referral processes, and after the drug has been dispensed. The new platform also allows specialty pharmacies to measure and validate a patient’s response to therapy.
The module can offer access to drug dispensing data, drug utilization data, and de-identified patient demographic data that can be utilized by various interested stakeholders: specialty pharmacies, pharmaceutical manufacturers, home infusion pharmacies, payers, pharmacy retailers, physicians, hospitals, and other health care groups tracking adherence and specialty drug compliance, the company stated.
Vision was developed to provide a real-time drilldown of how and where prescriptions are being filled to allow for better management of patients and specialty products. The web-based interface provides data about patient intake, days-to-fill, sales and dispensing information. Other capabilities include hub-based data capturing, tools for predictive analysis, spreadsheet exports, messaging and notifications.
"The Vision module enables pharmacies to perform real-time data analysis through a secure, HIPAA-compliant connection," stated Howard Barsky, chief information technology officer at Armada Health Care. "With Vision, we are able to provide true metrics for pharmacies and manufacturers to help them perform pre-dispensed data workflow analyses within a platform tightly integrated with our other proprietary tools: the ReachRx Online Therapy Management web application, Armada’s Specialty Pharmacy Network, and ApproveRx, our comprehensive prior authorization program."
Vision’s pre- and post-claims data can be used as a marker of patient adherence and compliance levels that health care providers can monitor through the program’s dashboard in order to anticipate and mitigate potential barriers to proper treatment with complex biologics, the company stated. These metrics may also help manufacturers make conclusions about usage and help company brand teams formulate sales strategies based on utilization and reimbursement trends on a region-by-region basis. In addition, the Vision Armada Analytics application also offers visibility into the insurance plan benefit design and co-pay programs associated with a specialty therapy.